Takeda assesses financial impact from Novartis’ withdrawal of marketing authorisation application for Xiidra
OSAKA: Takeda Pharmaceutical Company Limited announced the anticipated financial impact from Novartis Europharm Limited’s withdrawal of the Marketing Authorisation Application (MAA) for Xiidra in Europe, as posted on the European Medicines Agency’s website on June 26, 2020. Xiidra is the first and only prescription treatment approved by the U.S. Food and Drug Administration for both…